Statistics on Biotechnology Use  
Results by fields of operation
Business Sector Biotechnology indicators by branch of activity.
Unidades: specified in variables

;Total Companies;Services;Industry and Construction;Agriculture;
No. of companies carrying out R&D in Biotechnology;1.299;774;424;101;
%Companies according to biotechnology used: Genetic code;30,8;39,6;16,8;22,4;
%Companies according to biotechnology used: Functional units;38,4;42,6;34,2;23,7;
%Companies according to biotechnology used: Cellular and tissue culturing and engineering;21,5;26;14,3;17,4;
%Companies according to biotechnology used: Bioprocesses;50,8;40;74,7;32,7;
%Companies according to biotechnology used: Sub-cellular organisms;8,5;11,6;4,3;2,1;
%Companies according to biotechnology used: Bio-computing;24;34,5;9,1;6;
%Companies according to biotechnology used: Nanobiotechnology;12,1;16,8;6,1;1;
%Companies according to biotechnology used: Other;16,9;19;8,1;37,6;
Companies in which biotechnology activities are: Main and/or exclusive;559;442;97;21;
Companies in which biotechnology activities are: A secondary line of business;230;129;83;18;
Companies in which biotechnology activities are: A tool necessary for production;510;203;244;63;
%Company by field(s) of ultimate application of biotechnology use: Human Health;45,5;61,2;26,2;6,2;
%Company by field(s) of ultimate application of biotechnology use: Animal Health and Aquaculture;15,5;16,9;11;23,7;
%Company by field(s) of ultimate application of biotechnology use: Food products;32,3;21,7;51,5;32,9;
%Company by field(s) of ultimate application of biotechnology use: Agriculture and forest production;23,8;20,4;21,3;59,8;
%Company by field(s) of ultimate application of biotechnology use: Environment;15,6;16,3;14,9;13,4;
%Company by field(s) of ultimate application of biotechnology use: Industry;13,7;14,6;14,5;4,1;
Personnel in R&D in biotechnology (no. of persons);15.750;9.680;5.035;1.036;
Personnel in R&D in biotechnology (no. of persons): Research personnel;8.379;5.975;2.144;261;
Personnel in R&D in biotechnology (no. of persons): Technical and auxiliary personnel;7.371;3.704;2.891;775;
Personnel in R&D in biotechnology (no. of persons). Women;8.711;5.499;2.773;438;
Personnel in R&D in biotechnology (no. of persons). Women: Research personnel;4.510;3.287;1.119;104;
Personnel in R&D in biotechnology (no. of persons). Women: Technical and auxiliary personnel;4.200;2.212;1.655;333;
Personnel in R&D in biotechnology (FTE);11.528,6;7.260,7;3.657,9;610,1;
Personnel in R&D in biotechnology (FTE): Research personnel;6.342,7;4.531,8;1.631,6;179,3;
Personnel in R&D in biotechnology (FTE): Technical and auxiliary personnel;5.185,9;2.728,8;2.026,3;430,8;
Personnel in R&D in biotechnology (FTE). Women;6.539,7;4.129,4;2.140,4;270;
Personnel in R&D in biotechnology (FTE). Women: Research personnel;3.455,7;2.476,3;905,7;73,7;
Personnel in R&D in biotechnology (FTE). Women: Technical and auxiliary personnel;3.084;1.653;1.234,7;196,3;
Internal expenditure on R&D (thousands of euros);1.038.582;614.188;382.984;41.410;
1) By nature of the expense: Current expenses;940.091;558.041;344.917;37.132;
1.1) Remuneration to research personnel;321.570;213.833;98.160;9.577;
1.2) Remuneration to technicians and auxiliary personnel;194.836;94.194;87.790;12.851;
1.3) Other current expenses;423.685;250.013;158.967;14.704;
2) By nature of the expense: Capital expenses;98.492;56.147;38.067;4.278;
2.1) Land and buildings;10.199;6.083;2.952;1.165;
2.2) Equipment and instruments;72.584;38.296;32.431;1.858;
2.3) Acquisition of specific R&D software;5.721;3.732;1.850;138;
2.4) Otros productos de propiedad intelectual específicos para I+D;9.987;8.037;833;1.117;
1.1) By origin of the funds: Own funds;711.488;359.197;316.843;35.448;
1.2) By origin of the funds: From companies;121.738;107.930;9.208;4.600;
1.3) By origin of the funds: Public Administration funds;107.477;91.272;14.871;1.334;
1.4) By origin of the funds: From Universities;192;182;11;0;
1.5) By origin of the funds: From non profit private institutions;10.756;10.585;171;0;
1.6) By origin of the funds: Foreign funds;86.931;45.023;41.880;27;
Purchase of R&D services in biotechnology (thousands of euros);145.557;74.421;70.048;1.088;
Purchase of R&D services in biotechnology (thousands of euros): In Spain;95.915;52.406;42.780;729;
Purchase of R&D services in biotechnology (thousands of euros): Abroad;49.642;22.015;27.268;359;
%Companies that consider the following obstacles as very important considering biotechnology development: Access to capital;40,2;48,8;28;25,5;
%Companies that consider the following obstacles as very important considering biotechnology development: Access to technology / information;13,2;13;14,2;10,2;
%Companies that consider the following obstacles as very important considering biotechnology development: Access to human resources;19;20,3;17,3;16,3;
%Companies that consider the following obstacles as very important considering biotechnology development: Disconnection from the value chain;11,5;11,5;11,4;12,1;
%Companies that consider the following obstacles as very important considering biotechnology development: Lack of access to international markets;15,9;18;12,5;13,4;
%Companies that consider the following obstacles as very important considering biotechnology development: Lack of distribution and sales channels;17;20,3;11,3;15,3;
%Companies that consider the following obstacles as very important considering biotechnology development: Acceptance / public perception;16,4;16,5;16,5;16,1;
%Companies that consider the following obstacles as very important considering biotechnology development: Legal and regulatory requirements;40,5;42,9;37,1;36,7;
%Companies that consider the following obstacles as very important considering biotechnology development: Time / cost;55;58,7;48,7;52,9;
%Companies that consider the following obstacles as very important considering biotechnology development: Difficulty accessing patenting;21,9;22,3;20,1;26,3;
% Companies with income of an international origin related to biotechnological activities;23,5;26,2;22,4;7,2;
% Turnover representing income of an international origin related to biotechnological activities;1,9;4,1;1,6;2,2;
% Income of an international origin related to biotechnological activities distributed in: Income received from the EU;61,6;62,4;61,2;68,3;
% Income of an international origin related to biotechnological activities distributed in: Income received from other countries;38,4;37,6;38,8;31,7;
% Income of an international origin related to biotechnological activities by classification: Internacional trade in products and services;87,6;83,2;89,1;85;
% Income of an international origin related to biotechnological activities by classification: Milestones, royalties, sale or licensing of technologies outside Spain;10,9;12,2;10,8;0;
% Income of an international origin related with activities according to the classification: Operating source abroad;1,1;4,3;0,1;0;
% Income of an international origin related with activities according to the classification: Other;0,4;0,3;0;15;
Notas:
'.'=numeric piece of data equal to zero not resulting from rounding 

 FTE: Full Time Equivalent
Fuente: National Statistics Institute